{"Symbol": "MGNX", "AssetType": "Common Stock", "Name": "MacroGenics, Inc", "Description": "MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. It has strategic collaborations with Incyte Corporation; Zai Lab Limited; and I-Mab Biopharma. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "9704 Medical Center Drive, Rockville, MD, United States, 20850", "FullTimeEmployees": "384", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "1476695168", "EBITDA": "-166046000", "PERatio": "None", "PEGRatio": "0.01", "BookValue": "4.643", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-3.473", "RevenuePerShareTTM": "1.582", "ProfitMargin": "-2.1399", "OperatingMarginTTM": "-2.1748", "ReturnOnAssetsTTM": "-0.2976", "ReturnOnEquityTTM": "-0.6146", "RevenueTTM": "77872000", "GrossProfitTTM": "-131121000", "DilutedEPSTTM": "-3.385", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.912", "AnalystTargetPrice": "29", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "16.8835", "PriceToBookRatio": "5.8308", "EVToRevenue": "15.9367", "EVToEBITDA": "0", "Beta": "2.717", "52WeekHigh": "32.18", "52WeekLow": "4.04", "50DayMovingAverage": "27.0414", "200DayMovingAverage": "18.0129", "SharesOutstanding": "54091400", "SharesFloat": "43831670", "SharesShort": "4665699", "SharesShortPriorMonth": "4717963", "ShortRatio": "9", "ShortPercentOutstanding": "0.07", "ShortPercentFloat": "0.083", "PercentInsiders": "7.42", "PercentInstitutions": "94.183", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}